Posted by Michael Wonder on 17 Aug 2017
House Democrats start multiple sclerosis drug price probe
18 August 2017 - Biogen, Sanofi, Roche among drug makers who received letter.
House Democrats have started what they called an “in-depth” investigation into the pricing of drugs for neurological condition multiple sclerosis, the latest attempt by U.S. politicians to pressure manufacturers to lower costs.
Seven drugmakers -- Biogen, Sanofi, Novartis, Roche, Bayer, Merck KGaA’s EMD Serono unit and Teva Pharmaceuticals -- received letters requesting information on pricing strategies from Elijah Cummings and Peter Welch, two representatives who sit on the House Committee on Oversight and Government Reform.
